Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus: Focus on Bile Acid Sequestrants

Author： >

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.32, Iss.1, 2012-01, pp. : 1-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus

By Staels Bart Kuipers Folkert

Drugs, Vol. 67, Iss. 10, 2007-01 ,pp. : 1383-1392

Adis International

Access to resources Recommend Favorite

GLP-1 7-36 amide: potential in type 2 diabetes

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

GLP-1 agonists: a new approach for type 2 diabetes

Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele Bajaj Mandeep

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite